Cell-free dna guided targeted therapy leads to better survival in advanced non-small cell lung cancer

Santa clara, calif.--(business wire)--agilent technologies inc. (nyse: a) today announced a presentation by memorial sloan kettering cancer center (msk) at the upcoming annual meeting of the american society of clinical oncology (asco) to discuss the resolution ctdx lung, a laboratory-developed test (ldt) developed by resolution bioscience. the presentation titled overall survival with circulating tumor dna-guided therapy in advanced non-small cell lung cancer will present evidence for the clin
A Ratings Summary
A Quant Ranking